Special Issue

A Themed Issue in Honor of Professor Hartmut Derendorf — Outstanding Contributions in the Fields of Quantitative Clinical Pharmacology

Message from the Guest Editors

Hartmut Derendorf, University of Gainesville, Florida, US, was a renowned expert in pharmacokinetics and pharmacodynamics, with a specific interest in antibiotics. As such, he is considered one of the "fathers" of modern pharmacokinetics and pharmacometrics. He gave more than 900 presentations at national or international meetings to promote the use of these disciplines in order to optimize antibiotic dosing for each individual patient. He was an active member of many scientific societies, aiming at improving knowledge on the way antimicrobials should be dosed. He unexpectedly passed away in 2020, soon after his retirement. This Special Issue is dedicated to the memory of H. Derendorf. Contributions in the field of antibiotic pharmacokinetics and pharmacodynamics or pharmacometrics, as well as studies of drug-drug interactions involving anti-infective agents are especially encouraged. These works may include in vitro or in vivo data, mathematical models, as well as clinical trials, and concern registered antibiotics or molecules in development. Keywords: pharmacokinetics; pharmacodynamics; pharmacometrics; drug-drug interactions

Guest Editors

Prof. Dr. Françoise Van Bambeke

Prof. Dr. Sebastian Wicha

Dr. Markus Zeitlinger

Prof. Dr. Paul M. Tulkens

Deadline for manuscript submissions

closed (30 September 2022)



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/93025

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

